NASDAQ:ZYXI Zynex (ZYXI) Stock Price, News & Analysis $2.13 -0.03 (-1.16%) As of 03:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zynex Stock (NASDAQ:ZYXI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zynex alerts:Sign Up Key Stats Today's Range$1.93▼$2.1650-Day Range$2.16▼$8.2752-Week Range$1.95▼$12.84Volume272,097 shsAverage Volume149,978 shsMarket Capitalization$64.53 millionP/E Ratio14.23Dividend YieldN/APrice Target$10.25Consensus RatingHold Company OverviewZynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Read More… Remove Ads Zynex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreZYXI MarketRank™: Zynex scored higher than 69% of companies evaluated by MarketBeat, and ranked 258th out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingZynex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageZynex has only been the subject of 3 research reports in the past 90 days.Read more about Zynex's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth135.00% Earnings GrowthEarnings for Zynex are expected to grow by 135.00% in the coming year, from $0.20 to $0.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 13.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 20.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 13.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.16.Price to Book Value per Share RatioZynex has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zynex's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.43% of the float of Zynex has been sold short.Short Interest Ratio / Days to CoverZynex has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.Change versus previous monthShort interest in Zynex has recently decreased by 13.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.43% of the float of Zynex has been sold short.Short Interest Ratio / Days to CoverZynex has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.Change versus previous monthShort interest in Zynex has recently decreased by 13.15%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.11 News SentimentZynex has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for Zynex this week, compared to 4 articles on an average week.Search Interest5 people have searched for ZYXI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Zynex to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $148,300.00 in company stock.Percentage Held by Insiders52.13% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.68% of the stock of Zynex is held by institutions.Read more about Zynex's insider trading history. Receive ZYXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYXI Stock News HeadlinesZynex, Inc. Class Action: The Gross Law Firm Reminds Zynex, Inc. ...April 7 at 6:21 AM | gurufocus.comZynex, Inc. Class Action: The Gross Law Firm Reminds Zynex, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 - ZYXIApril 7 at 5:45 AM | prnewswire.comYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.April 7, 2025 | Premier Gold Co (Ad)ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zynex, Inc. ...April 6 at 7:20 PM | gurufocus.comFaruqi & Faruqi Reminds Zynex Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 - ZYXIApril 6 at 9:20 AM | globenewswire.comROSEN, LEADING TRIAL COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZYXIApril 5 at 3:10 PM | markets.businessinsider.comZynex Medical offers non-invasive and non-addictive pain solution NexWave - ICYMIApril 5 at 8:07 AM | proactiveinvestors.comROSEN, GLOBALLY REGARDED TRIAL COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZYXIApril 5 at 5:03 AM | markets.businessinsider.comSee More Headlines ZYXI Stock Analysis - Frequently Asked Questions How have ZYXI shares performed this year? Zynex's stock was trading at $8.01 on January 1st, 2025. Since then, ZYXI stock has decreased by 74.5% and is now trading at $2.0460. View the best growth stocks for 2025 here. How were Zynex's earnings last quarter? Zynex, Inc. (NASDAQ:ZYXI) released its quarterly earnings data on Tuesday, March, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.11. The company earned $45.98 million during the quarter, compared to analysts' expectations of $53.65 million. Zynex had a net margin of 2.49% and a trailing twelve-month return on equity of 13.05%. How do I buy shares of Zynex? Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zynex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zynex investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings3/11/2025Today4/07/2025Next Earnings (Estimated)4/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:ZYXI CIK846475 Webwww.zynex.com Phone(303) 703-4906FaxN/AEmployees770Year FoundedN/APrice Target and Rating Average Stock Price Target$10.25 High Stock Price Target$15.00 Low Stock Price Target$5.50 Potential Upside/Downside+374.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.09 Trailing P/E Ratio14.40 Forward P/E Ratio10.80 P/E GrowthN/ANet Income$9.73 million Net Margins2.49% Pretax Margin3.48% Return on Equity13.05% Return on Assets3.78% Debt Debt-to-Equity Ratio1.66 Current Ratio3.94 Quick Ratio3.15 Sales & Book Value Annual Sales$192.35 million Price / Sales0.34 Cash Flow$0.12 per share Price / Cash Flow18.01 Book Value$1.36 per share Price / Book1.59Miscellaneous Outstanding Shares30,227,000Free Float15,245,000Market Cap$65.29 million OptionableOptionable Beta1.09 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ZYXI) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zynex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.